Delaware
|
| |
6770
|
| |
85-3357217
|
(State or other jurisdiction of
incorporation or organization)
|
| |
(Primary Standard Industrial
Classification Code Number)
|
| |
(I.R.S. Employer
Identification Number)
|
Paul D. Tropp
Ropes & Gray LLP
1211 Avenue of the Americas
New York, NY 10036
(212) 596-9000
|
| |
Derek J. Dostal
Deanna L. Kirkpatrick
Davis Polk & Wardwell LLP
450 Lexington Avenue
New York, NY 10017
(212) 450-4000
|
Large accelerated filer ☐
|
| |
Accelerated filer ☐
|
| |
Non-accelerated filer ☒
|
| |
Smaller reporting company ☒
|
|
| |
|
| |
|
| |
Emerging growth company ☒
|
Title of Each Class of
Security Being Registered
|
| |
Amount Being
Registered
|
| |
Proposed Maximum
Offering Price per
Security(1)
|
| |
Proposed Maximum
Aggregate Offering
Price(1)
|
| |
Amount of
Registration Fee
|
Units, each consisting of one share of Class A common stock, $0.0001 par value, and one-half of one redeemable warrant(2)
|
| |
25,875,000 Units
|
| |
$10.00
|
| |
$258,750,000
|
| |
$28,230
|
Shares of Class A common stock included as part of the Units(3)
|
| |
25,875,000 Shares
|
| |
—
|
| |
—
|
| |
—(4)
|
Redeemable warrants included as part of the Units(3)
|
| |
12,937,500 Warrants
|
| |
—
|
| |
—
|
| |
—(4)
|
Total
|
| |
|
| |
|
| |
$258,750,000
|
| |
$28,230
|
(1)
|
Estimated solely for the purpose of calculating the registration fee.
|
(2)
|
Includes 3,375,000 units, consisting of 3,375,000 shares of Class A common stock and 1,687,500 redeemable warrants, that may be issued upon exercise of a 45-day option granted to the underwriter to cover over-allotments, if any.
|
(3)
|
Pursuant to Rule 416, there are also being registered an indeterminable number of additional securities as may be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.
|
(4)
|
No fee pursuant to Rule 457(g) under the Securities Act.
|
|
| |
Per Unit
|
| |
Total
|
Public offering price
|
| |
$10.00
|
| |
$225,000,000
|
Underwriting discounts and commissions(1)
|
| |
$0.55
|
| |
$12,375,000
|
Proceeds, before expenses, to HumanCo Acquisition Corp.
|
| |
$9.45
|
| |
$212,625,000
|
(1)
|
Includes $0.35 per unit, or $7,875,000 (or $9,056,250 if the underwriter’s over-allotment option is exercised in full) in the aggregate, payable to the underwriter for deferred underwriting commissions that will be placed in a trust account located in the United States as described herein. The deferred commissions will be released to the underwriter only on completion of an initial business combination, as described in this prospectus. Does not include certain fees and expenses payable to the underwriter in connection with this offering. See the section of this prospectus entitled “Underwriting” for a description of compensation and other items of value payable to the underwriter.
|
| | ||
| | ||
| | ||
| | ||
| | ||
| | ||
| | ||
| | ||
| | ||
| | ||
| | ||
| | ||
| | ||
| | ||
| | ||
| | ||
| | ||
| | ||
| |
•
|
“CAVU” are to CAVU Venture Partners III, LP;
|
•
|
“CAVU private placement” are to the private placement to CAVU of CAVU units occurring concurrently with the closing of this offering;
|
•
|
“CAVU shares” are to the shares of our Class A common stock included in the CAVU units;
|
•
|
“CAVU units” are to the units to be issued in the CAVU private placement;
|
•
|
“CAVU warrants” are to the warrants included in the CAVU units;
|
•
|
“common stock” are to our Class A common stock and our Class B common stock, collectively;
|
•
|
“directors” are to our current directors and our director nominees named in this prospectus;
|
•
|
“equity-linked securities” are to any debt or equity securities that are convertible, exercisable or exchangeable for shares of our Class A common stock issued in connection with our initial business combination, including, but not limited to, a private placement of equity or debt;
|
•
|
“founder shares” are to shares of our Class B common stock initially purchased by our sponsor in a private placement prior to this offering, and the shares of our Class A common stock issued upon the conversion thereof as provided herein (for the avoidance of doubt, such shares of Class A common stock will not be “public shares”);
|
•
|
“HumanCo” are, in the context of our sponsor, to HMCO Acquisition, LLC and, in all other contexts, to HumanCo LLC;
|
•
|
“initial stockholders” are to our sponsor and any other holders of founder shares prior to this offering (or their permitted transferees);
|
•
|
“management” or our “management team” are to our officers;
|
•
|
“private placement warrants” are to the warrants to be issued to our sponsor in a private placement concurrently with the closing of this offering;
|
•
|
“public shares” are to shares of our Class A common stock sold as part of the units in this offering (whether they are purchased in this offering or thereafter in the open market);
|
•
|
“public stockholders” are to the holders of our public shares, including our initial stockholders to the extent our initial stockholders purchase public shares, provided that each initial stockholder’s status as a “public stockholder” shall only exist with respect to such public shares;
|
•
|
“public warrants” are to our redeemable warrants sold as part of the units in this offering (whether they are purchased in this offering or thereafter in the open market), to the private placement warrants if held by third parties other than our sponsor (or its permitted transferees), and to any private placement warrants issued upon conversion of working capital loans that are sold to third parties that are not initial purchasers or members of our management team (or permitted transferees);
|
•
|
“sponsor” are to HumanCo Acquisition Holdings, LLC, a Delaware limited liability company, which is affiliated with HumanCo and CAVU;
|
•
|
“warrants” are to our redeemable warrants, which include the public warrants, the private placement warrants and the CAVU warrants; and
|
•
|
“we,” “us,” “company,” “our” or “our company” are to HumanCo Acquisition Corp.
|
○
|
Target identification and selection:
|
•
|
Actionable, proprietary deal flow based on highly successful track record and decades of industry relationships
|
•
|
Track record and value-add capabilities create preferred partner status with founders and CEOs
|
•
|
Frequent touch points and strong industry relationships across all verticals
|
•
|
Selection process that leverages our experience providing robust 360˚ value-add capabilities from operations to consumer-facing brand building
|
•
|
History of successful entry points in private acquisitions and in public equities
|
•
|
Extensive knowledge of public and private markets
|
•
|
Deep understanding of risks and shifting trends in H&W
|
○
|
Partnering with target company
|
•
|
Unparalleled in-house value-add capabilities and resources
|
•
|
Understanding the levers that drive stock performance, premium valuations and lower cost of capital
|
•
|
Deep industry network, from retail relationships to national media partners, built over decades
|
•
|
Established CPG platform ecosystem and preferential treatment and discounted rates with service providers
|
•
|
Ability to elevate companies through branding, marketing and revenue growth
|
•
|
History of top talent recruitment and development
|
•
|
Strong management team with founder-led culture;
|
•
|
High quality, differentiated products with mission-driven, health-forward approach;
|
•
|
Signs of market penetration with strong demonstrated performance in existing markets;
|
•
|
Good unit economics with strong quality of revenue and velocities;
|
•
|
Attractive, high-growth category with durable tailwinds; and
|
•
|
Path to become or already are an industry leader.
|
•
|
one share of Class A common stock; and
|
•
|
one-half of one redeemable warrant.
|
1
|
Assumes no exercise of the underwriter’s over-allotment option and the forfeiture by our sponsor of 843,750 shares of Class B common stock and includes an aggregate of 2,500,000 CAVU units sold concurrently with the closing of this offering.
|
2
|
Includes up to 843,750 shares of Class B common stock that are subject to forfeiture by our sponsor depending on the extent to which the underwriter’s over-allotment option is exercised.
|
3
|
Consists of 25,000,000 shares of Class A common stock (including 2,500,000 shares of Class A common stock included in the CAVU units) and 5,625,000 shares of Class B common stock. The Class B common stock is automatically convertible into shares of our Class A common stock one a one-for-one basis, subject to adjustment as described below adjacent to the caption“Founder shares conversion and anti-dilution rights.”
|
4
|
Includes 1,250,000 CAVU warrants.
|
•
|
30 days after the completion of our initial business combination, and
|
•
|
12 months from the closing of this offering;
|
•
|
in whole and not in part;
|
•
|
at a price of $0.01 per warrant;
|
•
|
upon a minimum of 30 days’ prior written notice of redemption, which we refer to as the 30-day redemption period;
|
•
|
if, and only if, the last reported sale price of our Class A common stock for any 10 trading days within a 20-trading day period ending on the third trading day prior to the date on which we send the notice of redemption to the warrant holders (the “Reference Value”) equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like and certain issuances of Class A common stock and equity-linked securities).
|
•
|
in whole and not in part;
|
•
|
at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption, provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to the table set forth under “Description of Securities—Warrants—Public Stockholders’ Warrants” based on the redemption date and the “fair market value” of our Class A common stock (as defined below);
|
•
|
if, and only if, the Reference Value equals or exceeds $10.00 per public share (as adjusted per stock splits, stock dividends, reorganizations, recapitalizations and the like and certain issuances of Class A common stock and equity-linked securities); and
|
•
|
if, and only if, the Reference Value is less than $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like and certain issuances of Class A common stock and equity-linked securities), the private placement warrants are also concurrently called for redemption on the same terms as the outstanding public warrants, as described above.
|
•
|
only holders of the Class B common stock have the right to vote on the election of directors prior to our initial business combination and holders of a majority of our shares of Class B common stock may remove a member of the board of directors for any reason;
|
•
|
the shares of Class B common stock automatically convert into shares of our Class A common stock at the time of our initial business combination, or at any time prior thereto at the option of the holder, on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, as described herein;
|
•
|
the shares of Class B common stock are subject to certain transfer restrictions, as described in more detail below;
|
•
|
our sponsor, each of our officers and directors and CAVU have entered into a letter agreement with us, pursuant to which they have agreed to (i) waive their redemption rights with respect to their founder shares, CAVU shares and public shares in connection with the completion of our initial business combination, (ii) waive their redemption rights with respect to their founder shares, CAVU shares and public shares in connection with a stockholder vote to approve an amendment to our amended and restated certificate of incorporation (A) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or to redeem 100% of our public shares and CAVU shares if we do not complete our initial business combination within 24 months from the closing of this offering or (B) with respect to any other provision relating to stockholders’ rights or pre-initial business combination activity and (iii) waive their rights to liquidating distributions from the trust account with respect to their founder shares if we fail to complete our initial
|
•
|
pursuant to the letter agreement, our sponsor, each of our officers and directors and CAVU have agreed to vote any founder shares and CAVU shares held by them and any public shares purchased during or after this offering (including in open market and privately negotiated transactions) in favor of our initial business combination. If we submit our initial business combination to our public stockholders for a vote, we will complete our initial business combination only if a majority of the outstanding shares of common stock voted are voted in favor of the initial business combination. As a result, in addition to the founder shares and CAVU shares, we would need only 7,187,501, or 31.9% (assuming all outstanding shares are voted and the underwriter’s over-allotment option is not exercised), of the 22,500,000 public shares sold in this offering to be voted in favor of an initial business combination in order to have our initial business combination approved. Assuming only the minimum number of shares representing a quorum are voted and the underwriter’s over-allotment option is not exercised, in addition to the founder shares and CAVU shares, we would not need any of the 22,500,000 public shares sold in this offering to be voted in favor of an initial business combination in order to have our initial business combination approved; and
|
•
|
the founder shares are entitled to registration rights.
|
•
|
the CAVU shares are subject to certain transfer restrictions, as described in more detail below;
|
•
|
CAVU, the holder of our CAVU units, has entered into a letter agreement with us, pursuant to which it has agreed to waive its redemption rights with respect to its CAVU shares in connection with the completion of our initial business combination;
|
•
|
pursuant to the letter agreement, CAVU has agreed to vote any CAVU shares held by it and any public shares purchased during or after this offering (including in open market and privately negotiated transactions) in favor of our initial business combination. If we submit our initial business combination to our public stockholders for a vote, we will complete our initial business combination only if a majority of the outstanding shares of common stock voted are voted in favor of the initial business combination. As a result, in addition to the founder shares and CAVU shares, we would need only 7,187,501, or 31.9% (assuming all outstanding shares are voted and the underwriter’s over-allotment option is not exercised), of the 22,500,000 public shares sold in this offering to be voted in favor of an initial business combination in order to have our initial business combination approved. Assuming only the minimum number of shares representing a quorum are voted and the underwriter’s over-allotment option is not exercised, in addition to the founder shares and CAVU shares, we would not need any of the 22,500,000 public shares
|
•
|
the CAVU shares are entitled to registration rights.
|
•
|
the net proceeds of this offering, the sale of the private placement warrants and the CAVU private placement not held in the trust account, which will be approximately $1,325,000 in working capital after the payment of approximately $1,000,000 in expenses relating to this offering; and
|
•
|
any loans or additional investments from our sponsor, members of our management team or their affiliates or other third parties, although they are under no obligation to advance funds or invest in us, and provided that any such loans will not have any claim on the proceeds held in the trust account unless such proceeds are released to us upon completion of an initial business combination.
|
•
|
conduct the redemptions pursuant to Rule 13e-4 and Regulation 14E of the Exchange Act, which regulate issuer tender offers, and
|
•
|
file tender offer documents with the SEC prior to completing our initial business combination which contain substantially the same financial and other information about the initial business combination and the redemption rights as is required under Regulation 14A of the Exchange Act, which regulates the solicitation of proxies.
|
•
|
conduct the redemptions in conjunction with a proxy solicitation pursuant to Regulation 14A of the Exchange Act, which regulates the solicitation of proxies, and not pursuant to the tender offer rules, and
|
•
|
file proxy materials with the SEC.
|
•
|
repayment of a loan of up to an aggregate of $300,000 made to us by our sponsor to cover offering related and organizational expenses;
|
•
|
reimbursement for any out-of-pocket expenses related to identifying, investigating and completing an initial business combination; and
|
•
|
repayment of loans which may be made by our sponsor or an affiliate of our sponsor or certain of our officers or directors to finance transaction costs in connection with an intended initial business combination, the terms of which have not been determined nor have any written agreements been executed with respect thereto. Up to $2,000,000 of such loans may be convertible into warrants, at a price of $1.00 per warrant at the option of the lender. The warrants would be identical to the private placement warrants, including as to exercise price, exercisability and exercise period.
|
|
| |
October 12,
2020
|
|
| |
Actual
|
Balance Sheet Data:
|
| |
|
Working capital (deficiency)
|
| |
$(57,000)
|
Total assets
|
| |
$104,000
|
Total liabilities
|
| |
$82,000
|
Stockholder’s equity
|
| |
$22,000
|
•
|
our being a company with no operating history and no revenues;
|
•
|
our ability to select an appropriate target business or businesses;
|
•
|
our ability to complete our initial business combination, particularly given competition from other blank check companies and financial and strategic buyers;
|
•
|
our expectations around the performance of the prospective target business or businesses, including competitive prospects of the business following our initial business combination;
|
•
|
our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination;
|
•
|
our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in approving our initial business combination, as a result of which they would then receive expense reimbursements;
|
•
|
our potential ability to obtain additional financing to complete our initial business combination;
|
•
|
the number, variety and characteristics of prospective target businesses;
|
•
|
our ability to consummate an initial business combination amidst the uncertainty resulting from the ongoing COVID-19 pandemic, and the effects of the ongoing pandemic on the H&W and related industries, the economy and any business or businesses with which we consummate our initial business combination;
|
•
|
the ability of our officers and directors to generate a number of potential acquisition opportunities;
|
•
|
our public securities’ potential liquidity and trading;
|
•
|
the lack of a market for our securities;
|
•
|
the use of proceeds not held in the trust account or available to us from interest income on the trust account balance;
|
•
|
the trust account not being subject to claims of third parties;
|
•
|
our financial performance following this offering; and
|
•
|
the other risks and uncertainties discussed in “Risk Factors” and elsewhere in this prospectus.
|
•
|
restrictions on the nature of our investments; and
|
•
|
restrictions on the issuance of securities, each of which may make it difficult for us to complete our initial business combination.
|
•
|
registration as an investment company;
|
•
|
adoption of a specific form of corporate structure; and
|
•
|
reporting, record keeping, voting, proxy and disclosure requirements and other rules and regulations.
|
•
|
may significantly dilute the equity interest of investors in this offering;
|
•
|
may subordinate the rights of holders of common stock if preferred stock is issued with rights senior to those afforded our common stock;
|
•
|
could cause a change of control if a substantial number of shares of our common stock are issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers and directors; and
|
•
|
may adversely affect prevailing market prices for our units, Class A common stock and/or warrants.
|
•
|
default and foreclosure on our assets if our operating revenues after an initial business combination are insufficient to repay our debt obligations;
|
•
|
acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant;
|
•
|
our immediate payment of all principal and accrued interest, if any, if the debt is payable on demand;
|
•
|
our inability to obtain necessary additional financing if the debt contains covenants restricting our ability to obtain such financing while the debt is outstanding;
|
•
|
our inability to pay dividends on our common stock;
|
•
|
using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends on our common stock if declared, our ability to pay expenses, make capital expenditures and acquisitions, and fund other general corporate purposes;
|
•
|
limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate;
|
•
|
increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation;
|
•
|
limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements and execution of our strategy; and
|
•
|
other disadvantages compared to our competitors who have less debt.
|
•
|
solely dependent upon the performance of a single business, property or asset, or
|
•
|
dependent upon the development or market acceptance of a single or limited number of products, processes or services.
|
•
|
a limited availability of market quotations for our securities;
|
•
|
reduced liquidity for our securities;
|
•
|
a determination that our Class A common stock is a “penny stock” which will require brokers trading in our Class A common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;
|
•
|
a limited amount of news and analyst coverage; and
|
•
|
a decreased ability to issue additional securities or obtain additional financing in the future.
|
(i)
|
we issue additional shares of Class A common stock or equity-linked securities for capital raising purposes in connection with the closing of our initial business combination at a Newly Issued Price of less than $9.20 per share (with such issue price or effective issue price to be determined in good faith by our board of directors and, (i) in the case of any such issuance to HumanCo, CAVU, our sponsor or any of their respective affiliates, without taking into account any founder shares or CAVU shares held by HumanCo, CAVU, our sponsor or such affiliates, as applicable, prior to such issuance, and (ii) to the extent that such issuance is made to HumanCo, CAVU or any of their respective affiliates, without taking into account the transfer of founder shares, CAVU shares or private placement warrants (including if such transfer is effectuated as a surrender to us and subsequent reissuance by us) by our sponsor, HumanCo or CAVU in connection with such issuance);
|
(ii)
|
the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial business combination on the date of the consummation of our initial business combination (net of redemptions); and
|
(iii)
|
the Market Value is below $9.20 per share, then the exercise price of the warrants will be adjusted to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger prices described under “Description of Securities—Redeemable Warrants—Public Stockholders’ Warrants—Redemption of warrants when the price per share of Class A common stock equals or exceeds $18.00” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the $10.00 per share redemption trigger price described under “Description of Securities—Redeemable Warrants—Public Stockholders’ Warrants—Redemption of warrants when the price per share of Class A common stock equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price.
|
•
|
the history and prospects of companies whose principal business is the acquisition of other companies;
|
•
|
prior offerings of those companies;
|
•
|
our prospects for acquiring an operating business;
|
•
|
a review of debt to equity ratios in leveraged transactions;
|
•
|
our capital structure;
|
•
|
an assessment of our management and their experience in identifying operating companies;
|
•
|
general conditions of the securities markets at the time of this offering; and
|
•
|
other factors as were deemed relevant.
|
•
|
we have a board that includes a majority of “independent directors,” as defined under the rules of Nasdaq;
|
•
|
we have a compensation committee of our board that is comprised entirely of independent directors with a written charter addressing the committee’s purpose and responsibilities; and
|
•
|
we have a nominating and corporate governance committee of our board that is comprised entirely of independent directors with a written charter addressing the committee’s purpose and responsibilities.
|
•
|
higher costs and difficulties inherent in managing cross-border business operations and complying with different commercial and legal requirements of overseas markets;
|
•
|
rules and regulations regarding currency redemption;
|
•
|
complex corporate withholding taxes on individuals;
|
•
|
laws governing the manner in which future business combinations may be effected;
|
•
|
tariffs and trade barriers;
|
•
|
regulations related to customs and import/export matters;
|
•
|
longer payment cycles and challenges in collecting accounts receivable;
|
•
|
tax issues, including but not limited to tax law changes and variations in tax laws as compared to the United States;
|
•
|
currency fluctuations and exchange controls;
|
•
|
rates of inflation;
|
•
|
cultural and language differences;
|
•
|
employment regulations;
|
•
|
data privacy;
|
•
|
changes in industry, regulatory or environmental standards within the jurisdictions where we operate;
|
•
|
public health or safety concerns and governmental restrictions, including those caused by outbreaks of pandemic disease such as the COVID-19 pandemic;
|
•
|
crime, strikes, riots, civil disturbances, terrorist attacks, natural disasters and wars;
|
•
|
deterioration of political relations with the United States; and
|
•
|
government appropriations of assets.
|
•
|
competition could reduce profit margins;
|
•
|
consumer preferences could change;
|
•
|
failure to maintain and manage supply chains effectively;
|
•
|
availability of organic and similar ingredients at competitive prices;
|
•
|
the H&W and related industries are susceptible to significant liability exposure. If liability claims are brought against us following our initial business combination, it could materially adversely affect our operations;
|
•
|
loss of, or business disruption at, non-affiliated distributors through which sales are made;
|
•
|
interruption in, disruption of or loss of operations at one or more manufacturing facilities;
|
•
|
inability to use trademarks; and
|
•
|
failure to comply with the requirements of independent third-party certification organizations or authorities.
|
|
| |
Without
Over-Allotment
Option
|
| |
Over-Allotment
Option
Exercised
|
Gross proceeds
|
| |
|
| |
|
Gross proceeds from units offered to public
|
| |
$225,000,000
|
| |
$258,750,000
|
Gross proceeds from private placement warrants
|
| |
$6,825,000
|
| |
$7,500,000
|
Gross proceeds from CAVU private placement
|
| |
$25,000,000
|
| |
$25,000,000
|
Total gross proceeds
|
| |
$256,825,000
|
| |
$291,250,000
|
Estimated offering expenses(1)
|
| |
|
| |
|
Underwriting commissions (2% of gross proceeds from units offered to public, excluding deferred portion)(2)
|
| |
$4,500,000
|
| |
$5,175,000
|
Legal fees and expenses
|
| |
$300,000
|
| |
$300,000
|
Accounting fees and expenses
|
| |
$40,000
|
| |
$40,000
|
SEC expenses
|
| |
$28,230
|
| |
$28,230
|
FINRA expenses
|
| |
$39,313
|
| |
$39,313
|
Nasdaq listing and filing fees
|
| |
$75,000
|
| |
$75,000
|
Director and officer liability insurance premiums
|
| |
$200,000
|
| |
$200,000
|
Printing and engraving expenses
|
| |
$35,000
|
| |
$35,000
|
Miscellaneous(3)
|
| |
$282,457
|
| |
$282,457
|
Total estimated offering expenses (other than underwriting commissions)
|
| |
$1,000,000
|
| |
$1,000,000
|
Proceeds after offering expenses
|
| |
$251,325,000
|
| |
$285,075,000
|
Held in trust account
|
| |
$250,000,000
|
| |
$283,750,000
|
% of public offering size
|
| |
111%
|
| |
110%
|
Not held in trust account
|
| |
$1,325,000
|
| |
$1,325,000
|
|
| |
Amount
|
| |
% of Total
|
Legal, accounting, due diligence, travel, and other expenses in connection with any business combination
|
| |
$250,000
|
| |
19%
|
Legal and accounting fees related to regulatory reporting obligations
|
| |
$125,000
|
| |
9%
|
Nasdaq continued listing fees
|
| |
$75,000
|
| |
6%
|
Other miscellaneous expenses
|
| |
$875,000
|
| |
66%
|
Total
|
| |
$1,325,000
|
| |
100%
|
(1)
|
A portion of the offering expenses have been paid from the proceeds of a loan from our sponsor of up to $300,000 as described in this prospectus. As of November 19, 2020, we had $83,000 outstanding under the promissory note with our sponsor. This loan will be repaid upon completion of this offering out of the proceeds that have been allocated for the payment of offering expenses (other than underwriting commissions) and amounts not to be held in the trust account. In the event that offering expenses are less than as set forth in this table, any such amounts will be used for post-closing working capital expenses. In the event that the offering expenses are more than as set forth in this table, we may fund such excess with funds not held in the trust account.
|
(2)
|
The underwriter has agreed to defer underwriting commissions equal to 3.5% of the gross proceeds of this offering. Upon completion of our initial business combination, $7,875,000 (or $9,056,250 if the underwriter’s over-allotment option is exercised in full), which constitutes the underwriter’s deferred commissions will be paid to the underwriter from the funds held in the trust account, and the remaining funds, less amounts released by the trustee to pay redeeming stockholders, will be released to us and can be used to pay all or a portion of the purchase price of the business or businesses with which our initial business combination occurs or for general corporate purposes, including payment of principal or interest on indebtedness incurred in connection with our initial business combination, to fund the purchases of other companies or for working capital. The underwriter will not be entitled to any interest accrued on the deferred underwriting commissions.
|
(3)
|
Includes organizational and administrative expenses and may include amounts related to the above-listed expenses in the event actual amounts exceed estimates.
|
(4)
|
These expenses are estimates only and do not include interest which may be available to us from the trust account. Our actual expenditures for some or all of these items may differ from the estimates set forth herein. For example, we may incur greater legal and accounting expenses than our current estimates in connection with negotiating and structuring our initial business combination based upon the level of complexity of such business combination. In the event we identify an initial business combination target in a specific industry subject to specific regulations, we may incur additional expenses associated with legal due diligence and the engagement of special legal counsel. In addition, our staffing needs may vary and, as a result, we may engage a number of consultants to assist with legal and financial due diligence. We do not anticipate any change in our intended use of proceeds, other than fluctuations among the current categories of allocated expenses, which fluctuations, to the extent they exceed current estimates for any specific category of expenses, would not be available for our expenses.
|
|
| |
Without Over-
Allotment
|
| |
With Over-
Allotment
|
||||||
Public offering price
|
| |
|
| |
$10.00
|
| |
|
| |
$10.00
|
Net tangible book value before this offering
|
| |
(0.01)
|
| |
|
| |
(0.01)
|
| |
|
Increase attributable to public stockholders and CAVU private placement
|
| |
0.56
|
| |
|
| |
0.50
|
| |
|
Pro forma net tangible book value after this offering, the sale of the private placement warrants and the CAVU private placement
|
| |
|
| |
0.55
|
| |
|
| |
0.49
|
Dilution to public stockholders
|
| |
|
| |
$9.45
|
| |
|
| |
$9.51
|
Percentage of dilution to public stockholders
|
| |
|
| |
94.5%
|
| |
|
| |
95.1%
|
|
| |
Shares Purchased
|
| |
Total Consideration
|
| |
Average
Price Per
Share
|
||||||
|
| |
Number
|
| |
Percentage
|
| |
Amount
|
| |
Percentage
|
| ||
Initial Stockholders(1)
|
| |
5,625,000
|
| |
18.4%
|
| |
$25,000
|
| |
0.01%
|
| |
$0.004
|
CAVU
|
| |
2,500,000
|
| |
8.1%
|
| |
$25,000,000
|
| |
10.00%
|
| |
$10.00
|
Public Stockholders
|
| |
22,500,000
|
| |
73.5%
|
| |
$225,000,000
|
| |
89.99%
|
| |
$10.00
|
|
| |
30,625,000
|
| |
100%
|
| |
$250,025,000
|
| |
100%
|
| |
|
(1)
|
Assumes no exercise of the underwriter’s over-allotment option and the corresponding forfeiture of an aggregate of 843,750 shares of Class B common stock held by our sponsor.
|
|
| |
Without Over-
Allotment
|
| |
With Over-
Allotment
|
Numerator:
|
| |
|
| |
|
Net tangible book value before this offering
|
| |
$(57,000)
|
| |
$(57,000)
|
Net proceeds from this offering, the sale of the private placement warrants and the CAVU private placement(1)
|
| |
251,325,000
|
| |
285,075,000
|
Plus: Offering costs accrued or paid in advance, excluded from tangible book value
|
| |
79,000
|
| |
79,000
|
Less: Deferred underwriting commissions
|
| |
(7,875,000)
|
| |
(9,056,250)
|
Less: Proceeds held in trust subject to redemption(2)
|
| |
(238,471,989)
|
| |
(271,040,742)
|
|
| |
$5,000,011
|
| |
$5,000,008
|
Denominator:
|
| |
|
| |
|
Shares of Class B common stock outstanding prior to this offering
|
| |
6,468,750
|
| |
6,468,750
|
Shares of Class B common stock forfeited if over-allotment is not exercised
|
| |
(843,750)
|
| |
—
|
Shares of Class A common stock included in the units offered
|
| |
22,500,000
|
| |
25,875,000
|
Shares of Class A common stock included in the CAVU units
|
| |
2,500,000
|
| |
2,500,000
|
Less: Shares subject to redemption
|
| |
(21,462,479)
|
| |
(24,716,050)
|
|
| |
9,162,521
|
| |
10,127,700
|
(1)
|
Expenses applied against gross proceeds include offering expenses of $1,000,000 and underwriting commissions of $4,500,000 without the over-allotment option exercise and $5,175,000 with the over-allotment option exercise (excluding deferred underwriting fees). See “Use of Proceeds.”
|
(2)
|
If we seek stockholder approval of our initial business combination and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, our sponsor, initial stockholders, directors, officers or their respective affiliates may purchase public shares or public warrants in privately negotiated transactions or in the open market either prior to or following the completion of our initial business combination. In the event of any such purchases of our shares prior to the completion of our initial business combination, the number of shares of Class A common stock subject to redemption will be reduced by the amount of any such purchases, increasing the pro forma net tangible book value per share. See “Proposed Business—Permitted Purchases of Our Securities.”
|
|
| |
October 12, 2020
|
|||
|
| |
Actual
|
| |
As Adjusted(1)
|
Note payable to related party(1)
|
| |
$—
|
| |
$—
|
Deferred underwriting commissions
|
| |
—
|
| |
7,875,000
|
Class A common stock subject to possible redemption; 0 and 21,462,479 shares, actual and as adjusted, respectively(2)
|
| |
—
|
| |
238,471,989
|
Preferred stock, $0.0001 par value, 1,000,000 shares authorized; none issued and outstanding, actual and as adjusted
|
| |
—
|
| |
—
|
Class A common stock, $0.0001 par value, 100,000,000 shares authorized; 0 and 3,537,521 shares issued and outstanding (excluding 0 and 21,462,479 shares subject to possible redemption), actual and as adjusted, respectively
|
| |
—
|
| |
354
|
Class B common stock, $0.0001 par value, 10,000,000 shares authorized, 6,468,750 and 5,625,000 shares issued and outstanding, actual and as adjusted, respectively(3)
|
| |
647
|
| |
563
|
Additional paid-in capital
|
| |
24,353
|
| |
5,002,094
|
Accumulated deficit
|
| |
(3,000)
|
| |
(3,000)
|
Total stockholders’ equity
|
| |
$22,000
|
| |
$5,000,011
|
Total capitalization
|
| |
$22,000
|
| |
$251,347,000
|
(1)
|
Our sponsor has agreed to loan us up to $300,000 to be used for a portion of the expenses of this offering. The “as adjusted” information gives effect to the repayment of this note out of the proceeds from this offering, the sale of the private placement warrants and the CAVU private placement. As of November 19, 2020, we had $83,000 outstanding under the promissory note with our sponsor.
|
(2)
|
Upon the completion of our initial business combination, we will provide our public stockholders with the opportunity to redeem their public shares for cash equal to their pro rata share of the aggregate amount then on deposit in the trust account (excluding any amounts then on deposit in the trust account that are allocable to the CAVU shares) as of two business days prior to the consummation of the initial business combination, including interest earned on the funds held in the trust account (excluding any interest earned on the funds held in the trust account that are allocable to the CAVU shares) and not previously released to us to pay our franchise and income taxes, subject to the limitations described herein whereby our net tangible assets will be maintained at a minimum of $5,000,001 upon consummation of our initial business combination and any limitations (including, but not limited to, cash requirements) created by the terms of the proposed initial business combination.
|
(3)
|
Actual share amount is prior to any forfeiture of shares of Class B common stock by our sponsor and as adjusted amount assumes no exercise of the underwriter’s over-allotment option, and, consequently, forfeiture of 843,750 shares of Class B common stock by our sponsor.
|
•
|
may significantly dilute the equity interest of investors in this offering, which dilution would increase if the anti-dilution provisions in the Class B common stock resulted in the issuance of shares of Class A common stock on a greater than one-to-one basis upon conversion of the Class B common stock;
|
•
|
may subordinate the rights of holders of our common stock if preferred stock is issued with rights senior to those afforded our common stock;
|
•
|
could cause a change in control if a substantial number of shares of our common stock is issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers and directors;
|
•
|
may have the effect of delaying or preventing a change of control of us by diluting the stock ownership or voting rights of a person seeking to obtain control of us; and
|
•
|
may adversely affect prevailing market prices for our Class A common stock and/or warrants.
|
•
|
default and foreclosure on our assets if our operating revenues after an initial business combination are insufficient to repay our debt obligations;
|
•
|
acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant;
|
•
|
our immediate payment of all principal and accrued interest, if any, if the debt is payable on demand;
|
•
|
our inability to obtain necessary additional financing if the debt contains covenants restricting our ability to obtain such financing while the debt is outstanding;
|
•
|
our inability to pay dividends on our common stock;
|
•
|
using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends on our common stock if declared, our ability to pay expenses, make capital expenditures and acquisitions, and fund other general corporate purposes;
|
•
|
limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate;
|
•
|
increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation;
|
•
|
limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, and execution of our strategy; and
|
•
|
other purposes and other disadvantages compared to our competitors who have less debt.
|
•
|
staffing for financial, accounting and external reporting areas, including segregation of duties;
|
•
|
reconciliation of accounts;
|
•
|
proper recording of expenses and liabilities in the period to which they relate;
|
•
|
evidence of internal review and approval of accounting transactions;
|
•
|
documentation of processes, assumptions and conclusions underlying significant estimates; and
|
•
|
documentation of accounting policies and procedures.
|
○
|
Target identification and selection:
|
•
|
Actionable, proprietary deal flow based on highly successful track record and decades of industry relationships
|
•
|
Track record and value-add capabilities create preferred partner status with founders and CEOs
|
•
|
Frequent touch points and strong industry relationships across all verticals
|
•
|
Selection process that leverages our experience providing robust 360˚ value-add capabilities from operations to consumer-facing brand building
|
•
|
History of successful entry points in private acquisitions and in public equities
|
•
|
Extensive knowledge of public and private markets
|
•
|
Deep understanding of risks and shifting trends in H&W
|
○
|
Partnering with target company
|
•
|
Unparalleled in-house value-add capabilities and resources
|
•
|
Understanding the levers that drive stock performance, premium valuations and lower cost of capital
|
•
|
Deep industry network, from retail relationships to national media partners, built over decades
|
•
|
Established CPG platform ecosystem and preferential treatment and discounted rates with service providers
|
•
|
Ability to elevate companies through branding, marketing and revenue growth
|
•
|
History of top talent recruitment and development
|
•
|
Strong management team with founder-led culture;
|
•
|
High quality, differentiated products with mission-driven, health-forward approach;
|
•
|
Signs of market penetration with strong demonstrated performance in existing markets;
|
•
|
Good unit economics with strong quality of revenue and velocities;
|
•
|
Attractive, high-growth category with durable tailwinds; and
|
•
|
Path to become or already are an industry leader.
|
Type of Transaction
|
| |
Whether
Stockholder
Approval is
Required
|
Purchase of assets
|
| |
No
|
Purchase of stock of target not involving a merger with the company
|
| |
No
|
Merger of target into a subsidiary of the company
|
| |
No
|
Merger of the company with a target
|
| |
Yes
|
•
|
we issue shares of Class A common stock that will be equal to or in excess of 20% of the number of shares of our Class A common stock then outstanding;
|
•
|
any of our directors, officers or substantial stockholders (as defined by Nasdaq listing rules) has a 5% or greater interest (or such persons collectively have a 10% or greater interest), directly or indirectly, in the target business or assets to be acquired or otherwise and the present or potential issuance of common stock could result in an increase in outstanding shares of common stock or voting power of 5% or more; or
|
•
|
the issuance or potential issuance of common stock will result in our undergoing a change of control.
|
•
|
the timing of the transaction, including in the event we determine stockholder approval would require additional time and there is either not enough time to seek stockholder approval or doing so would place the company at a disadvantage in the transaction or result in other additional burdens on the company;
|
•
|
the expected cost of holding a stockholder vote;
|
•
|
the risk that the stockholders would fail to approve the proposed business combination;
|
•
|
other time and budget constraints of the company; and
|
•
|
additional legal complexities of a proposed business combination that would be time-consuming and burdensome to present to stockholders.
|
•
|
conduct the redemptions pursuant to Rule 13e-4 and Regulation 14E of the Exchange Act, which regulate issuer tender offers, and
|
•
|
file tender offer documents with the SEC prior to completing our initial business combination which contain substantially the same financial and other information about the initial business combination and the redemption rights as is required under Regulation 14A of the Exchange Act, which regulates the solicitation of proxies.
|
•
|
conduct the redemptions in conjunction with a proxy solicitation pursuant to Regulation 14A of the Exchange Act, which regulates the solicitation of proxies, and not pursuant to the tender offer rules, and
|
•
|
file proxy materials with the SEC.
|
|
| |
Redemptions in
Connection with
Our Initial
Business Combination or Certain Stockholder Votes
to Amend our
Amended and Restated Certificate of Incorporation
|
| |
Other Permitted
Purchases of
Public Shares by
Us or Our Affiliates
|
| |
Redemptions if
We fail to Complete
an Initial Business
Combination
|
Calculation of redemption price
|
| |
Redemptions at the time of our initial business combination may be made pursuant to a tender offer or in connection with a stockholder vote. The redemption price will be the same whether we conduct redemptions pursuant to a tender offer or in connection with a stockholder vote. In either case, or in the case of redemptions in connection with a stockholder vote to approve an amendment to our amended and restated certificate of incorporation (i) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or to redeem 100% of our public shares and CAVU shares if we do not complete our initial business combination within 24 months from the closing of this offering or (ii) with respect to any other provision relating to stockholders’ rights or pre-initial business combination activity, our public stockholders may redeem their public
|
| |
If we seek stockholder approval of our initial business combination, our sponsor, directors, officers or their affiliates may purchase public shares in privately negotiated transactions or in the open market prior to or following completion of our initial business combination. There is no limit to the prices that our sponsor, directors, officers or their affiliates may pay in these transactions.
|
| |
If we do not complete our initial business combination within 24 months from the closing of this offering or during any Extension Period, we will redeem all public shares at a per-share price, payable in cash, equal to the aggregate amount, then on deposit in the trust account (which is initially anticipated to be $10.00 per public share including interest earned on the funds held in the trust account and not previously released
|
|
| |
Redemptions in
Connection with
Our Initial
Business Combination or Certain Stockholder Votes
to Amend our
Amended and Restated Certificate of Incorporation
|
| |
Other Permitted
Purchases of
Public Shares by
Us or Our Affiliates
|
| |
Redemptions if
We fail to Complete
an Initial Business
Combination
|
|
| |
shares for cash equal to the aggregate amount then on deposit in the trust account (excluding any amounts then on deposit in the trust account that are allocable to the CAVU shares) as of two business days prior to the consummation of the initial business combination (which is initially anticipated to be $10.00 per public share), including interest earned on the funds held in the trust account (excluding any interest earned on the funds held in the trust account that are allocable to the CAVU shares) and not previously released to us to pay our franchise and income taxes divided by the number of then outstanding public shares, subject to the limitation that no redemptions will take place, if all of the redemptions would cause our net tangible assets to be less than $5,000,001 upon consummation of our initial business combination and any limitations (including but not limited to cash requirements) agreed to in connection with the negotiation of terms of a proposed initial business combination.
|
| |
|
| |
to us to pay our franchise and income taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares.
|
|
| |
|
| |
|
| |
|
Impact to remaining stockholders
|
| |
The redemptions in connection with our initial business combination or certain stockholder votes to amend our amended and restated certificate of incorporation will reduce the book value per share for our remaining stockholders, who will bear the burden of the deferred underwriting commissions and taxes payable.
|
| |
If the permitted purchases described above are made, there would be no impact to our remaining stockholders because the purchase price would not be paid by us.
|
| |
The redemption of our public shares if we fail to complete our initial business combination will reduce the book value per share for the shares held by our initial stockholders, who will be our only remaining stockholders after such redemptions.
|
|
| |
Terms of Our Offering
|
| |
Terms Under a Rule 419
Offering
|
Escrow of offering proceeds
|
| |
Nasdaq rules provide that at least 90% of the gross proceeds from this offering, the sale of the private placement warrants and the CAVU private placement be deposited in a trust account. $250,000,000 of the net proceeds of this offering, the sale of the private placement warrants and the CAVU private placement will be deposited into a trust account in the United States with Continental Stock Transfer & Trust Company acting as trustee.
|
| |
Approximately $191,362,500 of the offering proceeds would be deposited into either an escrow account with an insured depositary institution or in a separate bank account established by a broker-dealer in which the broker-dealer acts as trustee for persons having the beneficial interests in the account.
|
|
| |
|
| |
|
Investment of net proceeds
|
| |
$250,000,000 of the net offering proceeds, the sale of the private placement warrants and the CAVU private placement held in trust will be invested only in U.S. government treasury bills with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations.
|
| |
Proceeds could be invested only in specified securities such as a money market fund meeting conditions of the Investment Company Act or in securities that are direct obligations of, or obligations guaranteed as to principal or interest by, the United States.
|
|
| |
|
| |
|
Receipt of interest on escrowed funds
|
| |
Interest on proceeds from the trust account to be paid to stockholders is reduced by (i) any taxes paid or payable, and (ii) in the event of our liquidation for failure to complete our initial business combination within the allotted time, up to $100,000 of net interest that may be released to us should we have no or insufficient working capital to fund the costs and expenses of our dissolution and liquidation.
|
| |
Interest on funds in escrow account would be held for the sole benefit of investors, unless and only after the funds held in escrow were released to us in connection with our completion of a business combination.
|
|
| |
|
| |
|
Limitation on fair value or net assets of target business
|
| |
Nasdaq listing rules require that our initial business combination must be with one or more target businesses that together have an aggregate fair market value equal to at least 80% of the value of the trust account (excluding any deferred underwriting fees and taxes payable on the income earned on the trust account) at the time of our signing a definitive agreement in connection with our initial business combination.
|
| |
The fair value or net assets of a target business must represent at least 80% of the maximum offering proceeds.
|
|
| |
|
| |
|
Trading of securities issued
|
| |
We expect the units will begin trading on or promptly after the date of this prospectus. The Class A common stock and warrants comprising the units will begin separate trading on the 52nd day following the date of this prospectus (or, if such date is not a business day, the following business day) unless the underwriter informs us of its decision to allow earlier separate trading, subject to our having filed a Current Report on Form 8-K containing an audited balance sheet reflecting our receipt of the gross proceeds at the closing of this offering and having issued a press
|
| |
No trading of the units or the underlying Class A common stock and warrants would be permitted until the completion of a business combination. During this period, the securities would be held in the escrow or trust account.
|
|
| |
Terms of Our Offering
|
| |
Terms Under a Rule 419
Offering
|
|
| |
release announcing when such separate trading will begin. We will file the Current Report on Form 8-K promptly after the closing of this offering. If the over-allotment option is exercised following the initial filing of such Current Report on Form 8-K, an additional Current Report on Form 8-K will be filed to provide updated financial information to reflect the exercise of the over-allotment option.
The units will automatically separate into their component parts and will not be traded after completion of our initial business combination.
|
| |
|
|
| |
|
| |
|
Exercise of the warrants
|
| |
The warrants cannot be exercised until the later of 30 days after the completion of our initial business combination or 12 months from the closing of this offering.
|
| |
The warrants could be exercised prior to the completion of a business combination, but securities received and cash paid in connection with the exercise would be deposited in the escrow or trust account.
|
|
| |
|
| |
|
Election to remain an investor
|
| |
We will provide our public stockholders with the opportunity to redeem their public shares for cash equal to their pro rata share of the aggregate amount then on deposit in the trust account (excluding any amounts then on deposit in the trust account that are allocable to the CAVU shares) as of two business days prior to the consummation of our initial business combination, including interest earned on the funds held in the trust account (excluding any interest earned on the funds held in the trust account that are allocable to the CAVU shares) and not previously released to us to pay our franchise and income taxes, upon the completion of our initial business combination, subject to the limitations described herein. We may not be required by law to hold a stockholder vote. We intend to give approximately 30 days (but not less than 10 days nor more than 60 days) prior written notice of any such meeting, if required, at which a vote shall be taken to approve our initial business combination. If we are not required by law and do not otherwise decide to hold a stockholder vote, we will, pursuant to our amended and restated certificate of incorporation, conduct the redemptions pursuant to the tender offer rules of the SEC and file tender offer documents with the SEC which will contain substantially the same financial and other information about the initial business combination and the redemption rights as is required under the SEC’s proxy rules. In the event we conduct redemptions pursuant to the tender offer rules, our offer to redeem will remain open for at least 20 business days, in accordance with Rule 14e-1(a)
|
| |
A prospectus containing information pertaining to the business combination required by the SEC would be sent to each investor. Each investor would be given the opportunity to notify the company in writing, within a period of no less than 20 business days and no more than 45 business days from the effective date of a post-effective amendment to the company’s registration statement, to decide if it elects to remain a stockholder of the company or require the return of its investment. If the company has not received the notification by the end of the 45th business day, funds and interest or dividends, if any, held in the trust or escrow account are automatically returned to the stockholder. Unless a sufficient number of investors elect to remain investors, all funds on deposit in the escrow
|
|
| |
Terms of Our Offering
|
| |
Terms Under a Rule 419
Offering
|
|
| |
under the Exchange Act, and we will not be permitted to complete our initial business combination until the expiration of the tender offer period. If, however, we hold a stockholder vote, we will, like many blank check companies, offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules. If we seek stockholder approval, we will complete our initial business combination only if a majority of the outstanding shares of common stock voted are voted in favor of the initial business combination. Additionally, each public stockholder may elect to redeem their public shares irrespective of whether they vote for or against the proposed transaction. A quorum for such meeting will consist of the holders present in person or by proxy of shares of outstanding capital stock of the company representing a majority of the voting power of all outstanding shares of capital stock of the company entitled to vote at such meeting.
|
| |
account must be returned to all of the investors and none of the securities are issued.
|
|
| |
|
| |
|
Business combination deadline
|
| |
If we do not complete an initial business combination within 24 months or during any Extension Period from the closing of this offering, we will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem 100% of the public shares and the CAVU shares at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account including interest earned on the funds held in the trust account and not previously released to us to pay our franchise and income taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares and CAVU shares, which redemption will completely extinguish public stockholders’ and holders of CAVU shares’ rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders and our board of directors, dissolve and liquidate, subject in each case to our obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.
|
| |
If a business combination has not been completed within 18 months after the effective date of the company’s registration statement, funds held in the trust or escrow account are returned to investors.
|
|
| |
|
| |
|
Limitation on redemption rights of stockholders holding more than 15% of the shares sold in this offering if we hold a
|
| |
If we seek stockholder approval of our initial business combination and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, our amended and restated certificate of incorporation will provide that a public stockholder (including our affiliates), together with any affiliate of such stockholder or any other
|
| |
Many blank check companies provide no restrictions on the ability of stockholders to redeem shares based on the number of shares held by such stockholders in connection
|
|
| |
Terms of Our Offering
|
| |
Terms Under a Rule 419
Offering
|
stockholder vote
|
| |
person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Exchange Act), will be restricted from seeking redemption rights with respect to Excess Shares (more than an aggregate of 15% of the shares sold in this offering). Our public stockholders’ inability to redeem Excess Shares will reduce their influence over our ability to complete our initial business combination and they could suffer a material loss on their investment in us if they sell any Excess Shares in open market transactions.
|
| |
with an initial business combination.
|
|
| |
|
| |
|
Tendering stock certificates in connection with a tender offer or redemption rights
|
| |
We may require our public stockholders seeking to exercise their redemption rights, whether they are record holders or hold their shares in “street name,” to either tender their certificates to our transfer agent prior to the date set forth in the tender offer documents mailed to such holders or up to two business days prior to the initial vote on the proposal to approve the initial business combination in the event we distribute proxy materials, or to deliver their shares to the transfer agent electronically using The Depository Trust Company’s DWAC System, at the holder’s option. The tender offer or proxy materials, as applicable, that we will furnish to holders of our public shares in connection with our initial business combination will indicate whether we are requiring public stockholders to satisfy such delivery requirements, which may include the requirement that a beneficial holder must identify itself in order to validly redeem its public shares. Accordingly, a public stockholder would have from the time we send out our tender offer materials until the close of the tender offer period, or up to two days prior to the vote on the initial business combination if we distribute proxy materials, as applicable, to tender its shares if it wishes to seek to exercise its redemption rights.
|
| |
In order to perfect redemption rights in connection with their business combinations, holders could vote against a proposed initial business combination and check a box on the proxy card indicating such holders were seeking to exercise their redemption rights. After the business combination was approved, the company would contact such stockholders to arrange for them to deliver their certificate to verify ownership.
|
|
| |
|
| |
|
Release of funds
|
| |
Except with respect to interest earned on the funds held in the trust account that may be released to us to pay our franchise and income tax obligations, the proceeds from this offering, the sale of the private placement warrants and the CAVU private placement held in the trust account will not be released from the trust account until the earliest to occur of: (i) the completion of our initial business combination, (ii) the redemption of any public shares properly submitted in connection with a stockholder vote to amend our amended and restated certificate of incorporation (A) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or to redeem 100% of our public shares and CAVU shares if we do not complete
|
| |
The proceeds held in the escrow account are not released until the earlier of the completion of a business combination or the failure to effect a business combination within the allotted time.
|
|
| |
Terms of Our Offering
|
| |
Terms Under a Rule 419
Offering
|
|
| |
our initial business combination within 24 months from the closing of this offering or (B) with respect to any other provision relating to stockholders’ rights or pre-business combination activity and (iii) the redemption of 100% of our public shares and CAVU shares if we do not complete an initial business combination within the required timeframe (subject to the requirements of applicable law). On the completion of our initial business combination, all amounts held in the trust account will be released to us, less amounts released to a separate account controlled by the trustee for disbursal to redeeming stockholders. We will use these funds to pay amounts due to any public stockholders who exercise their redemption rights as described above under “Redemption rights for public stockholders upon completion of our initial business combination,” to pay the underwriter its deferred underwriting commissions, to pay all or a portion of the consideration payable to the target or owners of the target of our initial business combination and to pay other expenses associated with our initial business combination.
|
| |
|
Name
|
| |
Age
|
| |
Position
|
Jason H. Karp
|
| |
44
|
| |
Executive Co-Chairman
|
Ross Berman
|
| |
46
|
| |
Chief Executive Officer and Director
|
Brett Thomas
|
| |
41
|
| |
President
|
Amy Zipper
|
| |
44
|
| |
Chief Operating Officer
|
Rohan Oza
|
| |
49
|
| |
Co-Chairman Nominee
|
Katrina “Kat” Cole
|
| |
42
|
| |
Director Nominee
|
John Foraker
|
| |
57
|
| |
Director Nominee
|
Dean Hollis
|
| |
60
|
| |
Director Nominee
|
Brian Kelley
|
| |
59
|
| |
Director Nominee
|
•
|
assisting board oversight of (1) the integrity of our financial statements, (2) our compliance with legal and regulatory requirements, (3) the independent registered public accounting firm’s qualifications and independence and (4) the performance of our internal audit function and the independent registered public accounting firm;
|
•
|
the appointment, compensation, retention, replacement, and oversight of the work of the independent registered public accounting firm engaged by us;
|
•
|
pre-approving all audit and permitted non-audit services to be provided by the independent registered public accounting firm engaged by us, and establishing pre-approval policies and procedures;
|
•
|
setting clear hiring policies for employees or former employees of the independent registered public accounting firm, including but not limited to, as required by applicable laws and regulations;
|
•
|
setting clear policies for audit partner rotation in compliance with applicable laws and regulations;
|
•
|
obtaining and reviewing a report, at least annually, from the independent registered public accounting firm describing (i) the independent registered public accounting firm’s internal quality-control procedures, (ii) any material issues raised by the most recent internal quality-control review, or peer review, of the audit firm, or by any inquiry or investigation by governmental or professional authorities within the preceding five years respecting one or more independent audits carried out by the firm and any steps taken to deal with such issues and (iii) all relationships between the independent registered public accounting firm and us to assess the independent registered public accounting firm’s independence;
|
•
|
meeting to review and discuss our annual audited financial statements and quarterly financial statements with management and the independent registered public accounting firm, including reviewing our specific disclosures under “Management’s Discussion and Analysis of Financial Condition and Results of Operations”;
|
•
|
reviewing and approving any related party transaction required to be disclosed pursuant to Item 404 of Regulation S-K promulgated by the SEC prior to us entering into such transaction; and
|
•
|
reviewing with management, the independent registered public accounting firm, and our legal advisors, as appropriate, any legal, regulatory or compliance matters, including any correspondence with regulators or government agencies and any employee complaints or published reports that raise material issues regarding our financial statements or accounting policies and any significant changes in accounting standards or rules promulgated by the Financial Accounting Standards Board, the SEC or other regulatory authorities.
|
•
|
reviewing and approving on an annual basis the corporate goals and objectives relevant to our Chief Executive Officer’s compensation, if any is paid by us, evaluating our Chief Executive Officer’s performance in light of such goals and objectives and determining and approving the remuneration (if any) of our Chief Executive Officer based on such evaluation;
|
•
|
reviewing and making recommendations on an annual basis to our board of directors with respect to (or approving, if such authority is so delegated by our board of directors) the compensation, if any is paid by us, and any incentive-compensation and equity-based plans that are subject to board approval of our other officers;
|
•
|
reviewing on an annual basis our executive compensation policies and plans;
|
•
|
implementing and administering our incentive compensation equity-based remuneration plans;
|
•
|
assisting management in complying with our proxy statement and annual report disclosure requirements;
|
•
|
approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our officers and employees;
|
•
|
if required, producing a report on executive compensation to be included in our annual proxy statement; and
|
•
|
reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors.
|
•
|
None of our officers or directors is required to commit his or her full time to our affairs and, accordingly, may have conflicts of interest in allocating his or her time among various business activities.
|
•
|
In the course of their other business activities, our officers and directors may become aware of investment and business opportunities which may be appropriate for presentation to us as well as the other entities with which they are affiliated. Our management may have conflicts of interest in determining to which entity a particular business opportunity should be presented.
|
•
|
Our sponsor, each of our officers and directors and CAVU have agreed to (i) waive their redemption rights with respect to their founder shares, CAVU shares and public shares in connection with the completion of our initial business combination, (ii) waive their redemption rights with respect to their founder shares, CAVU shares and public shares in connection with a stockholder vote to approve an amendment to our amended and restated certificate of incorporation (A) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or to redeem 100% of our public shares and CAVU shares if we do not complete our initial business combination within 24 months from the closing of this offering or (B) with respect to any other provision relating to stockholders’ rights or pre-initial business combination activity and (iii) waive their rights to liquidating distributions from the trust account with respect to their founder shares if we fail to complete our initial business combination within 24 months from the closing of this offering or during any Extension Period, although they will be entitled to liquidating distributions from the trust account with respect to any public shares and CAVU shares they hold if we fail to complete our initial business combination within the prescribed timeframe. CAVU has not waived its rights to liquidating distributions from the trust account with respect to its CAVU shares if we fail to complete our initial business combination within 24 months from the closing of this offering or during any Extension Period. If we do not complete our initial business combination within such applicable time period, the proceeds of the sale of the private placement warrants and the CAVU private placement held in the trust account will be used to fund the redemption of our public shares and our CAVU shares, and the private placement warrants and CAVU warrants will expire worthless. With certain limited exceptions, the founder shares and CAVU shares will not be transferable or assignable by until the earlier of: (A) one year after the completion of our initial business combination or (B) subsequent to our initial business combination, (x) if the last reported sale price of our Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after our initial business combination, or (y) the date on which we complete a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of our stockholders having the right to exchange their shares of Class A common stock for cash, securities or other property. With certain limited exceptions, the private placement warrants, the CAVU warrants and the common stock underlying such warrants will not be transferable, assignable or saleable by our sponsor, CAVU or their respective permitted transferees until 30 days after the completion of our initial business combination.
|
•
|
Our officers and directors may have a conflict of interest with respect to evaluating a particular business combination if the retention or resignation of any such officers and directors were to be included by a target business as a condition to any agreement with respect to our initial business combination.
|
•
|
Our sponsor, officers or directors may have a conflict of interest with respect to evaluating a business combination and financing arrangements as we may obtain loans from our sponsor or an affiliate of our sponsor or certain of our officers or directors to finance transaction costs in connection with an intended initial business combination. Up to $2,000,000 of such loans may be convertible into warrants at a price of $1.00 per warrant at the option of the lender. Such warrants would be identical to the private placement warrants, including as to exercise price, exercisability and exercise period.
|
•
|
the corporation could financially undertake the opportunity;
|
•
|
the opportunity is within the corporation’s line of business; and
|
•
|
it would not be fair to the corporation and its stockholders for the opportunity not to be brought to the attention of the corporation.
|
Individual
|
| |
Entity
|
| |
Entity’s Business
|
| |
Affiliation
|
Jason H. Karp
|
| |
HumanCo LLC
|
| |
Financial and Operational Services
|
| |
Co-Founder and
Chief Executive Officer
|
|
| |
|
| |
|
| |
|
|
| |
Hu Master Holdings LLC
|
| |
Food Products
|
| |
Chairman and Co-Founder
|
|
| |
|
| |
|
| |
|
|
| |
Airgraft Inc.
|
| |
Healthcare Technology
|
| |
Director
|
|
| |
|
| |
|
| |
|
|
| |
Coconut Bliss LLC
|
| |
Food Products
|
| |
Director
|
|
| |
|
| |
|
| |
|
Ross Berman
|
| |
HumanCo LLC
|
| |
Financial and Operational Services
|
| |
Co-Founder and President
|
|
| |
|
| |
|
| |
|
|
| |
Hu Master Holdings LLC
|
| |
Food Products
|
| |
Director
|
|
| |
|
| |
|
| |
|
|
| |
Hardee Fresh LLC
|
| |
Vertical Farming
|
| |
Director
|
|
| |
|
| |
|
| |
|
|
| |
Coconut Bliss LLC
|
| |
Food Products
|
| |
Director
|
|
| |
|
| |
|
| |
|
Individual
|
| |
Entity
|
| |
Entity’s Business
|
| |
Affiliation
|
Brett Thomas
|
| |
CAVU Venture Partners III, LP
|
| |
Investment Management
|
| |
Managing Partner
|
|
| |
|
| |
|
| |
|
|
| |
CAVU Venture Partners
|
| |
Investment Management
|
| |
Manager
|
|
| |
|
| |
|
| |
|
|
| |
Green Park Snacks Inc.
|
| |
Consumer Products
|
| |
Director
|
|
| |
|
| |
|
| |
|
|
| |
OSEA International
|
| |
Consumer Products
|
| |
Director
|
|
| |
|
| |
|
| |
|
|
| |
Once Upon a Farm, LLC
|
| |
Consumer Products
|
| |
Director
|
|
| |
|
| |
|
| |
|
Amy Zipper
|
| |
HumanCo LLC
|
| |
Financial and Operational Services
|
| |
Chief Operating Officer
|
|
| |
|
| |
|
| |
|
Rohan Oza
|
| |
CAVU Venture Partners III, LP
|
| |
Investment Management
|
| |
Managing Partner
|
|
| |
|
| |
|
| |
|
|
| |
CAVU Venture Partners
|
| |
Investment Management
|
| |
Manager
|
|
| |
|
| |
|
| |
|
|
| |
Health Ade LLC
|
| |
Consumer Products
|
| |
Director
|
|
| |
|
| |
|
| |
|
|
| |
Wild Things Snacks Inc.
|
| |
Consumer Products
|
| |
Director
|
|
| |
|
| |
|
| |
|
|
| |
Bulletproof Inc.
|
| |
Consumer Products
|
| |
Director
|
|
| |
|
| |
|
| |
|
|
| |
VNGR Beverage LLC
|
| |
Consumer Products
|
| |
Director
|
|
| |
|
| |
|
| |
|
|
| |
Beekeeper’s Naturals
|
| |
Consumer Products
|
| |
Director
|
|
| |
|
| |
|
| |
|
|
| |
Cue Health Inc.
|
| |
Consumer Products
|
| |
Director
|
|
| |
|
| |
|
| |
|
Kat Cole
|
| |
Focus Brands LLC
|
| |
Foodservice Brands
|
| |
Chief Operating Officer and President
|
|
| |
|
| |
|
| |
|
|
| |
Milk Bar
|
| |
Food Products
|
| |
Director
|
|
| |
|
| |
|
| |
|
John Foraker
|
| |
Once Upon a Farm, LLC
|
| |
Consumer Products
|
| |
Co-Founder and Chief Executive Officer
|
|
| |
|
| |
|
| |
|
Dean Hollis
|
| |
SunOpta Inc.
|
| |
Food Products
|
| |
Chairman
|
|
| |
|
| |
|
| |
|
|
| |
Oaktree Capital Management
|
| |
Asset Management
|
| |
Senior Advisor
|
|
| |
|
| |
|
| |
|
|
| |
The Hain Celestial Group, Inc.
|
| |
Consumer Products
|
| |
Chairman
|
|
| |
|
| |
|
| |
|
|
| |
JBS USA Holdings, Inc.
|
| |
Food Products
|
| |
Member of Independent Advisory Board
|
|
| |
|
| |
|
| |
|
|
| |
Boardriders
|
| |
Action Sports and Lifestyle
|
| |
Chairman
|
|
| |
|
| |
|
| |
|
|
| |
Diventures
|
| |
Action Sports and Lifestyle
|
| |
Founder
|
|
| |
|
| |
|
| |
|
Brian Kelley
|
| |
PearlRock Partners
|
| |
Financial Services
|
| |
Chairman and Chief Executive Officer
|
•
|
each person known by us to be the beneficial owner of more than 5% of our outstanding shares of common stock;
|
•
|
each of our officers and directors that beneficially owns shares of our common stock; and
|
•
|
all our officers, directors and director nominees as a group.
|
|
| |
Before Offering
|
| |
After Offering
|
||||||
Name and Address of Beneficial Owner(1)
|
| |
Number of Shares
Beneficially
Owned(2)
|
| |
Approximate
Percentage of
Outstanding
Common Stock
|
| |
Number of Shares
Beneficially
Owned(2)
|
| |
Approximate
Percentage of
Outstanding
Common Stock
|
HumanCo Acquisition Holdings, LLC(3)
|
| |
6,258,750
|
| |
96.8%
|
| |
5,415,000
|
| |
17.7%
|
CAVU Venture Partners III, LP(4)
|
| |
—
|
| |
—
|
| |
2,500,000
|
| |
8.2%
|
Jason H. Karp
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
Ross Berman
|
| |
75,000
|
| |
1.2%
|
| |
75,000
|
| |
*
|
Brett Thomas(4)
|
| |
—
|
| |
—
|
| |
2,500,000
|
| |
8.2%
|
Amy Zipper
|
| |
25,000
|
| |
*
|
| |
25,000
|
| |
*
|
Rohan Oza(4)
|
| |
—
|
| |
—
|
| |
2,500,000
|
| |
8.2%
|
Kat Cole
|
| |
25,000
|
| |
*
|
| |
25,000
|
| |
*
|
John Foraker
|
| |
25,000
|
| |
*
|
| |
25,000
|
| |
*
|
Dean Hollis
|
| |
25,000
|
| |
*
|
| |
25,000
|
| |
*
|
Brian Kelley
|
| |
25,000
|
| |
*
|
| |
25,000
|
| |
*
|
All officers, directors and director nominees as a group (nine individuals)
|
| |
200,000
|
| |
3.1%
|
| |
5,200,000
|
| |
17.0%
|
*
|
less than 1%
|
(1)
|
Unless otherwise noted, the business address of each of the following entities or individuals is c/o HumanCo Acquisition Corp., P.O. Box 90608, Austin, TX 78709.
|
(2)
|
Interests shown consist solely of founder shares, classified as shares of Class B common stock. Such shares are convertible into shares of Class A common stock on a one-for-one basis, subject to adjustment, as described in the section of this prospectus entitled “Description of Securities.”
|
(3)
|
The shares reported above are held in the name of our sponsor. Our sponsor is managed by a board of managers consisting of Jason H. Karp, Ross Berman and Brett Thomas. Any action by our sponsor with respect to our company or the shares reported above, including voting and dispositive decisions, requires a unanimous vote of the managers of the board of managers. Under the so-called
|
(4)
|
Represents shares held by CAVU Venture Partners III, LP, which is controlled indirectly by Rohan Oza and Brett Thomas. Messrs. Oza and Thomas may be deemed to beneficially own 2,500,000 shares of Class A common stock and ultimately exercise voting and dispositive power of the securities held by CAVU Venture Partners III, LP. Voting and disposition decisions with respect to such securities are made by Messrs. Oza and Thomas, each of whom disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.
|
•
|
Repayment of a loan of up to an aggregate of $300,000 made to us by our sponsor to cover offering related and organizational expenses;
|
•
|
Reimbursement for any out-of-pocket expenses related to identifying, investigating and completing an initial business combination; and
|
•
|
Repayment of loans which may be made by our sponsor or an affiliate of our sponsor or certain of our officers and directors to finance transaction costs in connection with an intended initial business combination, the terms of which have not been determined nor have any written agreements been executed with respect thereto. Up to $2,000,000 of such loans may be convertible into warrants at a price of $1.00 per warrant at the option of the lender.
|
•
|
25,000,000 shares of Class A common stock underlying the units being offered in this offering and the CAVU units; and
|
•
|
5,625,000 shares of Class B common stock held by our initial stockholders.
|
•
|
in whole and not in part;
|
•
|
at a price of $0.01 per warrant;
|
•
|
upon a minimum of 30 days’ prior written notice of redemption to each warrant holder; and
|
•
|
if, and only if, the last reported sale price of the Class A common stock for any 10 trading days within a 20-trading day period ending three trading days before we send the notice of redemption to the warrant holders (which we refer to as the “Reference Value”) equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading “—Redeemable Warrants—Public Stockholders’ Warrants—Anti-Dilution Adjustments”).
|
•
|
in whole and not in part;
|
•
|
at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption, provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to the table below, based on the redemption date and the “fair market value” of our Class A common stock (as defined below in the immediately following paragraph) except as otherwise described below;
|
•
|
if, and only if, the Reference Value (as defined above under the heading “—Redeemable Warrants—Public Stockholders’ Warrants—Redemption of warrants when the price per share of Class A common stock equals or exceeds $18.00”) equals or exceeds $10.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading “—Redeemable Warrants—Public Stockholders’ Warrants—Anti-Dilution Adjustments”); and
|
•
|
if the Reference Value is less than $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading “ —Redeemable Warrants—Public Stockholders’ Warrants—Anti-Dilution Adjustments”), the private placement warrants are also concurrently called for redemption on the same terms as the outstanding public warrants, as described above.
|
•
|
If we do not complete our initial business combination within 24 months from the closing of this offering or during any Extension Period, we will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter subject to lawfully available funds therefor, redeem 100% of the public shares and the CAVU shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account including interest earned on the funds held in the trust account and not previously released to us to pay our franchise and income taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares and CAVU shares, which redemption will completely
|
•
|
Prior to or in connection with our initial business combination (other than pursuant to the CAVU private placement), we may not issue additional shares of capital stock that would entitle the holders thereof to (i) receive funds from the trust account or (ii) vote on our initial business combination;
|
•
|
Although we do not intend to enter into an initial business combination with a target business that is affiliated with HumanCo, CAVU, or our sponsor, officers or directors, we are not prohibited from doing so. In the event we enter into such a transaction, we, or a committee of independent directors, will, to the extent required by applicable law or based upon the direction of our board of directors or a committee thereof, obtain an opinion from an independent investment banking firm or another entity that commonly renders valuation opinions that such an initial business combination is fair to our company from a financial point of view;
|
•
|
If a stockholder vote on our initial business combination is not required by law and we do not decide to hold a stockholder vote for business or other reasons, we will offer to redeem our public shares pursuant to Rule 13e-4 and Regulation 14E of the Exchange Act, and will file tender offer documents with the SEC prior to completing our initial business combination which contain substantially the same financial and other information about our initial business combination and the redemption rights as is required under Regulation 14A of the Exchange Act; whether or not we maintain our registration under the our Exchange Act or our listing on Nasdaq, we will provide our public stockholders with the opportunity to redeem their public shares by one of the two methods listed above;
|
•
|
Our initial business combination will be approved by a majority of our independent directors;
|
•
|
Our initial business combination must occur with one or more businesses that together have an aggregate fair market value of at least 80% of the net assets held in the trust account (excluding the deferred underwriting fees and taxes payable) at the time of our signing a definitive agreement in connection with our initial business combination;
|
•
|
If our stockholders approve an amendment to our amended and restated certificate of incorporation (i) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or to redeem 100% of our public shares and CAVU shares if we do not complete our initial business combination within 24 months from the closing of this offering or (ii) with respect to any other provision relating to stockholders’ rights or pre-business combination activity, we will provide our public stockholders with the opportunity to redeem all or a portion of their shares of Class A common stock upon such approval at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account (excluding any amounts then on deposit in the trust account that are allocable to the CAVU shares), including interest earned on the funds held in the trust account (excluding any interest earned on the funds held in the trust account that are allocable to the CAVU shares) and not previously released to us to pay our franchise and income taxes, divided by the number of then outstanding public shares; and
|
•
|
We will not effectuate our initial business combination with another blank check company or a similar company with nominal operations.
|
•
|
prior to such time, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;
|
•
|
upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of our voting stock outstanding at the time the transaction commenced, excluding certain shares; or
|
•
|
at or subsequent to that time, the business combination is approved by our board of directors and by the affirmative vote of holders of at least 662∕3% of the outstanding voting stock that is not owned by the interested stockholder.
|
•
|
1% of the total number of shares of Class A common stock then outstanding, which will equal 250,000 shares immediately after this offering (or 283,750 if the underwriter’s over-allotment option is exercised in full); or
|
•
|
the average weekly reported trading volume of the Class A common stock during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale.
|
•
|
the issuer of the securities that was formerly a shell company has ceased to be a shell company;
|
•
|
the issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act;
|
•
|
the issuer of the securities has filed all Exchange Act reports and materials required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Current Reports on Form 8-K; and
|
•
|
at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company.
|
•
|
our sponsor, founders, officers or directors;
|
•
|
financial institutions or financial services entities;
|
•
|
broker-dealers;
|
•
|
governments or agencies or instrumentalities thereof;
|
•
|
regulated investment companies;
|
•
|
S corporations;
|
•
|
real estate investment trusts;
|
•
|
expatriates or former long-term residents of the United States;
|
•
|
persons that actually or constructively own five percent or more (by vote or value) of our shares;
|
•
|
insurance companies;
|
•
|
dealers or traders subject to a mark-to-market method of tax accounting with respect to the securities;
|
•
|
accrual-method taxpayers who are required under Section 451(b) of the Internal Revenue Code of 1986, as amended (the “Code”), to recognize income for U.S. federal income tax purposes no later than when such income is taken into account in applicable financial statements;
|
•
|
persons holding the securities as part of a “straddle,” hedge, integrated transaction or similar transaction;
|
•
|
U.S. holders (as defined below) whose functional currency is not the U.S. dollar;
|
•
|
partnerships or other pass-through entities for U.S. federal income tax purposes and any beneficial owners of such entities; and
|
•
|
tax-exempt entities.
|
•
|
an individual who is a citizen or resident of the United States;
|
•
|
a corporation (or other entity taxable as a corporation) organized in or under the laws of the United States, any state thereof or the District of Columbia;
|
•
|
an estate the income of which is includible in gross income for U.S. federal income tax purposes regardless of its source; or
|
•
|
a trust, if (i) a court within the United States is able to exercise primary supervision over the administration of the trust and one or more United States persons (as defined in the Code) have authority to control all substantial decisions of the trust or (ii) it has a valid election in effect under Treasury Regulations to be treated as a United States person.
|
•
|
a non-resident alien individual (other than certain former citizens and residents of the United States subject to U.S. tax as expatriates);
|
•
|
a foreign corporation; or
|
•
|
an estate or trust that is not a U.S. holder;
|
•
|
the gain is effectively connected with the conduct of a trade or business by the Non-U.S. holder within the United States (and, under certain income tax treaties, is attributable to a United States permanent establishment or fixed base maintained by the Non-U.S. holder); or
|
•
|
we are or have been a “United States real property holding corporation” for U.S. federal income tax purposes at any time during the shorter of the five-year period ending on the date of disposition or the period that the Non-U.S. holder held our Class A common stock, and, in the case where shares of our Class A common stock are regularly traded on an established securities market, the Non-U.S. holder has owned, directly or constructively, more than five percent of our Class A common stock at any time within the shorter of the five-year period preceding the disposition or such Non-U.S. holder’s holding period for the shares of our Class A common stock. There can be no assurance that our Class A common stock will be treated as regularly traded on an established securities market for this purpose.
|
Underwriter
|
| |
Number of Units
|
Citigroup Global Markets Inc.
|
| |
|
Total
|
| |
22,500,000
|
|
| |
Per Unit(1)
|
| |
Total(1)
|
||||||
|
| |
Without Over-
allotment
|
| |
With Over-
allotment
|
| |
Without Over-
allotment
|
| |
With Over-
allotment
|
Underwriting Discounts and Commissions paid by us
|
| |
$0.55
|
| |
$0.55
|
| |
$12,375,000
|
| |
$13,231,250
|
(1)
|
Includes $0.35 per unit, or $7,875,000 (or $9,056,250 if the underwriter’s over-allotment option is exercised in full) in the aggregate payable to the underwriter for deferred underwriting commissions to be placed in a trust account located in the United States as described herein. The deferred commissions will be released to the underwriter only on completion of an initial business combination, in an amount equal to $0.35 multiplied by the number of shares of Class A common stock sold as part of the units in this offering, as described in this prospectus.
|
•
|
the purchaser is entitled under applicable provincial securities laws to purchase the units without the benefit of a prospectus qualified under those securities laws as it is an “accredited investor” as defined under National Instrument 45-106—Prospectus Exemptions,
|
•
|
the purchaser is a “permitted client” as defined in National Instrument 31-103—Registration Requirements, Exemptions and Ongoing Registrant Obligations,
|
•
|
where required by law, the purchaser is purchasing as principal and not as agent, and
|
•
|
the purchaser has reviewed the text above under Resale Restrictions.
|
(a)
|
to any legal entity which is a qualified investor as defined under the Prospectus Regulation;
|
(b)
|
to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation), subject to obtaining the prior consent of the underwriter for any such offer; or
|
(c)
|
in any other circumstances falling within Article 1(4) of the Prospectus Regulation,
|
(a)
|
it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment activity (within the meaning of section 21 of FSMA) to persons who have professional experience in matters relating to investments falling with Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 or in circumstances in which section 21 of FSMA does not apply to the company; and
|
(b)
|
it has complied with, and will comply with all applicable provisions of FSMA with respect to anything done by it in relation to the units in, from or otherwise involving the United Kingdom.
|
•
|
a “sophisticated investor” under section 708(8)(a) or (b) of the Corporations Act;
|
•
|
a “sophisticated investor” under section 708(8)(c) or (d) of the Corporations Act and that you have provided an accountant’s certificate to the Company which complies with the requirements of section 708(8)(c)(i) or (ii) of the Corporations Act and related regulations before the offer has been made;
|
•
|
a person associated with the Company under Section 708(12) of the Corporations Act; or
|
•
|
a “professional investor” within the meaning of section 708(11)(a) or (b) of the Corporations Act.
|
ASSETS
|
| |
|
Current asset – cash
|
| |
$25,000
|
Deferred offering costs
|
| |
79,000
|
Total Assets
|
| |
$104,000
|
|
| |
|
LIABILITIES AND STOCKHOLDER’S EQUITY
|
| |
|
Current Liabilities:
|
| |
|
Accrued expenses
|
| |
$3,000
|
Accrued offering costs
|
| |
79,000
|
Total Current Liabilities
|
| |
82,000
|
|
| |
|
Commitments and contingencies
|
| |
|
|
| |
|
Stockholder’s Equity:
|
| |
|
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding
|
| |
—
|
Class A common stock, $0.0001 par value; 100,000,000 shares authorized; none issued and outstanding
|
| |
—
|
Class B common stock, $0.0001 par value; 10,000,000 shares authorized; 6,468,750 shares issued and outstanding(1)
|
| |
647
|
Additional paid-in capital
|
| |
24,353
|
Accumulated deficit
|
| |
(3,000)
|
Total Stockholder’s Equity
|
| |
22,000
|
Total Liabilities and Stockholder’s Equity
|
| |
$104,000
|
(1)
|
Includes an aggregate of up to 843,750 shares of Class B common stock subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters (see Note 5).
|
Formation costs
|
| |
$3,000
|
Net loss
|
| |
$(3,000)
|
|
| |
|
Weighted average shares outstanding, basic and diluted(1)
|
| |
5,625,000
|
|
| |
|
Basic and diluted net loss per common share
|
| |
$(0.00)
|
(1)
|
Excludes an aggregate of up to 843,750 shares of Class B common stock subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters (see Note 5).
|
|
| |
Class B
Common Stock
|
| |
Additional
Paid-in
Capital
|
| |
Accumulated
Deficit
|
| |
Total
Stockholder’s
Equity
|
|||
|
| |
Shares
|
| |
Amount
|
| ||||||||
Balance, October 5, 2020 (inception)
|
| |
—
|
| |
$—
|
| |
$—
|
| |
$—
|
| |
$—
|
Issuance of Class B common stock to Sponsor(1)
|
| |
6,468,750
|
| |
647
|
| |
24,353
|
| |
—
|
| |
25,000
|
Net loss
|
| |
—
|
| |
—
|
| |
—
|
| |
(3,000)
|
| |
(3,000)
|
Balance, October 12, 2020
|
| |
6,468,750
|
| |
$647
|
| |
$24,353
|
| |
$(3,000)
|
| |
$22,000
|
(1)
|
Includes an aggregate of up to 843,750 shares of Class B common stock subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters (see Note 5).
|
Cash flows from operating activities:
|
| |
|
Net loss
|
| |
$(3,000)
|
Changes in operating assets and liabilities:
|
| |
|
Accrued expenses
|
| |
3,000
|
Net cash used in operating activities
|
| |
—
|
|
| |
|
Cash Flows from Financing Activities
|
| |
|
Proceeds from issuance of Class B common stock to Sponsor
|
| |
25,000
|
Net cash provided by financing activities
|
| |
25,000
|
|
| |
|
Net change in cash
|
| |
25,000
|
Cash at beginning of period
|
| |
—
|
Cash at end of period
|
| |
$25,000
|
|
| |
|
Non-cash financing activities:
|
| |
|
Deferred offering costs included in accrued offering costs
|
| |
$79,000
|
•
|
in whole and not in part;
|
•
|
at a price of $0.01 per Public Warrant;
|
•
|
upon a minimum of 30 days' prior written notice of redemption to each warrant holder; and
|
•
|
if, and only if, the last reported sale price of the Class A common stock for any 10 trading days within a 20-trading day period ending three trading days before the Company sends the notice of redemption to the warrant holders (the “Reference Value”) equals or exceeds $18.00 per share.
|
•
|
in whole and not in part;
|
•
|
at $0.10 per warrant upon a minimum of 30 days' prior written notice of redemption, provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares based on the redemption date and the fair market value of the shares of Class A common stock;
|
•
|
if, and only if, the Reference Value equals or exceeds $10.00 per share; and
|
•
|
if the Reference Value is less than $18.00 per share, the Private Placement Warrants are also concurrently called for redemption on the same terms as the outstanding Public Warrants, as described above.
|
Item 13.
|
Other Expenses of Issuance and Distribution.
|
Legal fees and expenses
|
| |
$300,000
|
Accounting fees and expenses
|
| |
$40,000
|
SEC expenses
|
| |
$28,230
|
FINRA expenses
|
| |
$39,313
|
Travel and road show
|
| |
—
|
Nasdaq listing expenses
|
| |
$75,000
|
Director and officer insurance
|
| |
$200,000
|
Printing and engraving expenses
|
| |
$35,000
|
Miscellaneous(1)
|
| |
$282,457
|
Total
|
| |
$1,000,000
|
(1)
|
This amount represents additional expenses that may be incurred by us in connection with the offering over and above those specifically listed above, including transfer agent and trustee fees.
|
Item 14.
|
Indemnification of Directors and Officers.
|
(a)
|
A corporation shall have power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person’s conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that the person’s conduct was unlawful.
|
(b)
|
A corporation shall have power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys’ fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to which
|
(c)
|
To the extent that a present or former director or officer of a corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in subsections (a) and (b) of this section, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection therewith.
|
(d)
|
Any indemnification under subsections (a) and (b) of this section (unless ordered by a court) shall be made by the corporation only as authorized in the specific case upon a determination that indemnification of the present or former director, officer, employee or agent is proper in the circumstances because the person has met the applicable standard of conduct set forth in subsections (a) and (b) of this section. Such determination shall be made, with respect to a person who is a director or officer at the time of such determination, (1) by a majority vote of the directors who are not parties to such action, suit or proceeding, even though less than a quorum, or (2) by a committee of such directors designated by majority vote of such directors, even though less than a quorum, or (3) if there are no such directors, or if such directors so direct, by independent legal counsel in a written opinion, or (4) by the stockholders.
|
(e)
|
Expenses (including attorneys’ fees) incurred by an officer or director in defending any civil, criminal, administrative or investigative action, suit or proceeding may be paid by the corporation in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined that such person is not entitled to be indemnified by the corporation as authorized in this section. Such expenses (including attorneys’ fees) incurred by former officers and directors or other employees and agents may be so paid upon such terms and conditions, if any, as the corporation deems appropriate.
|
(f)
|
The indemnification and advancement of expenses provided by, or granted pursuant to, the other subsections of this section shall not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person’s official capacity and as to action in another capacity while holding such office. A right to indemnification or to advancement of expenses arising under a provision of the certificate of incorporation or a bylaw shall not be eliminated or impaired by an amendment to such provision after the occurrence of the act or omission that is the subject of the civil, criminal, administrative or investigative action, suit or proceeding for which indemnification or advancement of expenses is sought, unless the provision in effect at the time of such act or omission explicitly authorizes such elimination or impairment after such action or omission has occurred.
|
(g)
|
A corporation shall have power to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person’s status as such, whether or not the corporation would have the power to indemnify such person against such liability under this section.
|
(h)
|
For purposes of this section, references to “the corporation” shall include, in addition to the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, and employees or agents, so that any person who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee or agent of another corporation,
|
(i)
|
For purposes of this section, references to “other enterprises” shall include employee benefit plans; references to “fines” shall include any excise taxes assessed on a person with respect to any employee benefit plan; and references to “serving at the request of the corporation” shall include any service as a director, officer, employee or agent of the corporation which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner “not opposed to the best interests of the corporation” as referred to in this section.
|
(j)
|
The indemnification and advancement of expenses provided by, or granted pursuant to, this section shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of the heirs, executors and administrators of such a person.
|
(k)
|
The Court of Chancery is hereby vested with exclusive jurisdiction to hear and determine all actions for advancement of expenses or indemnification brought under this section or under any bylaw, agreement, vote of stockholders or disinterested directors, or otherwise. The Court of Chancery may summarily determine a corporation’s obligation to advance expenses (including attorneys’ fees).
|
Item 15.
|
Recent Sales of Unregistered Securities.
|
Item 16.
|
Exhibits and Financial Statement Schedules.
|
(a)
|
Exhibits. The following exhibits are filed as part of this registration statement:
|
Exhibit
No.
|
| |
Description
|
1.1*
|
| |
Form of Underwriting Agreement
|
| |
Certificate of Incorporation
|
|
3.2*
|
| |
Form of Amended and Restated Certificate of Incorporation
|
| |
Bylaws
|
|
| |
Specimen Unit Certificate
|
|
| |
Specimen Class A Common Stock Certificate
|
|
4.3*
|
| |
Specimen Warrant Certificate (included in Exhibit 4.4)
|
4.4*
|
| |
Form of Warrant Agreement between Continental Stock Transfer & Trust Company and the Registrant
|
5.1*
|
| |
Opinion of Ropes & Gray LLP
|
10.1*
|
| |
Form of Letter Agreement among the Registrant, HumanCo Acquisition Holdings, LLC, CAVU Venture Partners III, LP and each of the officers and directors of the Registrant
|
10.2*
|
| |
Form of Investment Management Trust Agreement between Continental Stock Transfer & Trust Company and the Registrant
|
| |
Securities Subscription Agreement, dated October 12, 2020, between the Registrant and HumanCo Acquisition Holdings, LLC
|
|
| |
Form of Private Placement Warrant Purchase Agreement between the Registrant and HumanCo Acquisition Holdings, LLC
|
|
| |
Form of Private Placement Unit Purchase Agreement between the Registrant and CAVU Venture Partners III, LP
|
|
10.6*
|
| |
Form of Registration and Stockholder Rights Agreement between the Registrant and certain securityholders
|
| |
Form of Indemnity Agreement
|
|
| |
Promissory Note issued in favor of HumanCo Acquisition Holdings, LLC, dated October 12, 2020
|
|
| |
Consent of WithumSmith+Brown, PC
|
|
23.2*
|
| |
Consent of Ropes & Gray LLP (included in Exhibit 5.1)
|
| |
Power of Attorney (included on the signature page of this Registration Statement)
|
|
| |
Consent of Rohan Oza
|
Exhibit
No.
|
| |
Description
|
| |
Consent of Kat Cole
|
|
| |
Consent of John Foraker
|
|
| |
Consent of Dean Hollis
|
|
| |
Consent of Brian Kelley
|
*
|
To be filed by amendment.
|
**
|
Filed herewith.
|
(b)
|
Financial Statements. See page F-1 for an index to the financial statements included in the registration statement.
|
Item 17.
|
Undertakings.
|
(a)
|
The undersigned registrant hereby undertakes to provide to the underwriter at the closing specified in the underwriting agreements, certificates in such denominations and registered in such names as required by the underwriter to permit prompt delivery to each purchaser.
|
(b)
|
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.
|
(c)
|
The undersigned registrant hereby undertakes that for the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
|
|
| |
HumanCo Acquisition Corp.
|
||||||
|
| |
|
| |
|
| |
|
|
| |
By:
|
| |
/s/ Ross Berman
|
|||
|
| |
|
| |
Name:
|
| |
Ross Berman
|
|
| |
|
| |
Title:
|
| |
Chief Executive Officer
|
Signature
|
| |
Title
|
| |
Date
|
|
| |
|
| |
|
/s/ Jason H. Karp
|
| |
Executive Co-Chairman
|
| |
November 20, 2020
|
Jason H. Karp
|
| |||||
|
| |
|
| |
|
/s/ Ross Berman
|
| |
Chief Executive Officer and Director
(Principal Executive Officer)
|
| |
November 20, 2020
|
Ross Berman
|
| |||||
|
| |
|
| |
|
/s/ Amy Zipper
|
| |
Chief Operating Officer
(Principal Financial and Accounting Officer)
|
| |
November 20, 2020
|
Amy Zipper
|
|
•
|
the numerator shall be equal to the sum of (A) 25% of all shares of Class A Common Stock issued or issuable (upon the conversion or exercise of any equity-linked securities or otherwise) by the Corporation, related to or in connection with
the consummation of the Business Combination (excluding any securities issued or issuable to any seller in the Business Combination) plus (B) the number of shares of Class B Common Stock issued and outstanding prior to the closing of the
Business Combination; and
|
•
|
the denominator shall be the number of shares of Class B Common Stock issued and outstanding prior to the closing of the Business Combination.
|
Name
|
Address
|
|
Samad Khan
|
Ropes & Gray LLP
|
|
Prudential Tower
800 Boylston Street
Boston, MA 02199
|
By:
|
/s/ Samad Khan
|
|
Name:
|
Samad Khan
|
|
Title:
|
Sole Incorporator
|
NUMBER
U-
|
UNITS
|
|
||
Authorized Signatory
|
Transfer Agent and Registrar
|
TEN COM
|
—
|
as tenants in common
|
UNIF GIFT
MIN ACT
|
—
|
Custodian
|
||
TEN ENT
|
—
|
as tenants by the entireties
|
(Cust)
|
(Minor)
|
|||
JT TEN
|
—
|
as joint tenants with right of survivorship and not as tenants in common
|
under Uniform Gifts to Minors Act
|
||||
(State)
|
|
(PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING ZIP CODE, OF ASSIGNEE) |
Dated
|
|||
Notice: The signature to this assignment must correspond with the name as written upon the face of the certificate in every particular, without alteration or enlargement or any change whatever.
|
THE SIGNATURE(S) MUST BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE
17Ad-15 (OR ANY SUCCESSOR RULE) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED).
|
NUMBER
|
SHARES
|
C-
|
|
CUSIP [●]
|
Chief Executive Officer
|
|
Chief Financial Officer
|
|
(PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER(S) OF ASSIGNEE(S))
|
|
|
|
|
Dated:
|
|||
NOTICE: THE SIGNATURE(S) TO THIS
ASSIGNMENT MUST CORRESPOND WITH THE
NAME AS WRITTEN UPON THE FACE OF THE
CERTIFICATE IN EVERY PARTICULAR,
WITHOUT ALTERATION OR ENLARGEMENT OR
ANY CHANGE WHATEVER.
|
By:
|
HumanCo Acquisition Holdings, LLC
|
October 12, 2020
|
P.O. Box 90608
|
|
Austin, TX 78709
|
Very truly yours,
|
||
HUMANCO ACQUISITION CORP.
|
||
By:
|
/s/ Amy Zipper
|
|
Name:
|
Amy Zipper
|
|
Title:
|
Chief Operating Officer
|
By:
|
/s/ Ross Berman
|
|
Name:
|
Ross Berman
|
|
Title:
|
Manager
|
COMPANY:
|
|
HUMANCO ACQUISITION CORP.
|
By:
|
Name:
|
|
Title:
|
PURCHASER:
|
|
HUMANCO ACQUISITION HOLDINGS, LLC
|
By:
|
Name:
|
|
Title:
|
COMPANY:
|
||
HUMANCO ACQUISITION CORP.
|
||
By:
|
||
Name:
|
||
Title:
|
||
PURCHASER:
|
||
CAVU VENTURE PARTNERS III, LP
|
||
By:
|
||
Name:
|
||
Title:
|
Attn:
|
with a copy to:
|
Ropes & Gray LLP | |
|
1211 Avenue of the Americas
|
|
|
New York, NY 10036
|
|
|
Attention: Paul Tropp
|
|
|
Email: paul.tropp@ropesgray.com
|
Company:
|
HumanCo Acquisition Corp.
|
By:
|
Name:
|
|
Title:
|
|
Indemnitee:
|
|
Name:
|
Principal Amount: up to $300,000
|
Dated as of October 12, 2020
|
HUMANCO ACQUISITION CORP.
|
||
By:
|
/s/ Amy Zipper
|
|
Name:
|
Amy Zipper
|
|
Title:
|
Chief Operating Officer
|
By:
|
/s/ Ross Berman
|
|
Name:
|
Ross Berman
|
|
Title:
|
Manager
|
Dated: November 15, 2020
|
/s/ Rohan Oza
|
Rohan Oza
|
Dated: November 13, 2020
|
/s/ Katrina Cole
|
Katrina Cole
|
Dated: November 3, 2020
|
/s/ John Foraker
|
John Foraker
|
Dated: November 3, 2020
|
/s/ Dean Hollis
|
Dean Hollis
|
Dated: November 13, 2020
|
/s/ Brian Kelley
|
Brian Kelley
|